MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System
MWN-AI** Summary
MedWell Ai, Inc. (OTCQB: MWAI), a Florida-based company, has announced the signing of a Letter of Intent (LOI) to establish a pioneering vertically integrated regenerative wellness ecosystem in the United States. This innovative initiative will organize MedWell Ai into three main divisions: a national pharmaceutical distribution and telemedicine platform, a portfolio of surgical and cosmetic centers along with a men’s healthcare franchise, and an advanced biologics and product innovation group.
As part of the strategy, MedWell Ai plans to acquire several key entities, including Ageless Cosmetic Surgery Centers and Apollo BioWellness, alongside its subsidiary, Evolutionary Biologics. Moreover, the company is expanding its own rapid growth subsidiary, MedWell USA, focusing on distributing GLP-1 and peptide-based products, and launching a new 24/7 telehealth platform named TeleMD, LLC.
The outlook for the consolidated company is promising, with projected revenues exceeding $25 million for 2026 based on trailing revenues of $14 million in 2025, assuming successful transactions and adequate funding. The regenerative medicine market, a crucial aspect of MedWell Ai's vision, was valued at approximately $35.5 billion in 2024 and is expected to reach over $169 billion by 2034, reflecting a substantial growth trajectory.
CEO Steve Rubakh emphasized the company's commitment to reducing supply chain inefficiencies and enhancing quality control through this consolidation. The goal is to create a complete wellness ecosystem that not only streamlines operations but also positions MedWell Ai as a leader in the regenerative wellness sector. The company is open to further strategic acquisitions in pursuit of establishing its dominance in the evolving wellness market.
MWN-AI** Analysis
MedWell Ai, Inc. (OTCQB: MWAI) has recently signed a Letter of Intent to create a vertically integrated health and wellness platform, marking a significant strategic move in the burgeoning regenerative wellness market. The initiative to consolidate operations into three core divisions reflects a comprehensive approach to capitalize on a growing industry with projected revenues reaching $169 billion by 2034.
Investors should consider the implications of this LOI, as the consolidation is anticipated to provide economies of scale and streamline operations by vertically integrating distribution, laboratories, and product development. Given MedWell's projection to achieve over $25 million in revenues for 2026 with conservative EBITDA margins of at least 20%, the firm is positioned for robust financial growth if operational milestones are met successfully.
The regenerative wellness market, currently valued at approximately USD 35.5 billion, is growing significantly, especially in North America where high healthcare expenditure and advanced biotech regulatory frameworks are aiding developments. The company’s focus on integrating advanced biologics and emerging technologies, particularly in the fast-growing fields of stem cell therapies and gene editing, aligns well with market dynamics.
Investors should remain alert to the forthcoming completion of their due diligence process and related outcomes, as successful acquisition closures could lead to substantial value creation. Additionally, the appointment of a seasoned management team will be pivotal in executing MedWell's vision and navigating competitive pressures in this rapidly evolving sector.
Potential investors should also weigh the inherent risks of investments in early-stage biotechnology firms, including regulatory hurdles and market competition. However, the overall growth trajectory of the regenerative wellness sector, combined with MedWell’s strategic initiatives, makes this stock a compelling consideration for those looking to capitalize on long-term health and wellness trends.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CLEARWATER, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN – MedWell Ai, Inc ("Company") (OTCQB: MWAI) is pleased to announce the signing of a Letter of Intent (“LOI”) to create a vertically integrated health, wellness and longevity platform.
New MedWell Ai, Inc will be organized across three core divisions: (1) national pharma distribution and telemed platform, (2) nationwide portfolio of premium surgical and cosmetic centers and men’s healthcare franchise brand and (3) advanced biologics and product innovation group.
The Company will acquire, consolidate and operate the following divisions:
- Ageless Cosmetic Surgery Centers, Inc., headquartered in Garden City, NY.
- Apollo BioWellness, Inc. (OTC: KOAN) and its subsidiary Evolutionary Biologics, Inc and other aesthetic and cosmetic technologies and products.
- MedWell USA, LLC, currently operating and rapidly growing subsidiary, focused on:
- (1) Distribution of GLP-1 and Peptides based products, manufactured by 503B facilities
- (2) Soon to be launching TeleMD, LLC - 24/7 telehealth platform.
Based on trailing revenues of $14 million in 2025, the consolidated Company is projected to generate annual revenues, exceeding $25 million in 2026 (assuming adequate funding and successful closing), and conservative EBITDA margins of at least 20%.
All parties have begun the due diligence process with the goal of closing the transactions within 60 days.
- Market Size: The Global Regenerative Medicine Market, a core component of the regenerative wellness ecosystem, was valued at approximately USD 35.5 billion in 2024 and is projected to reach over USD 169 billion by 2034, growing at a CAGR of roughly 16% to 23%. The broader global wellness economy, which includes elements of regenerative health, reached a record USD 6.3 trillion in 2023 and is forecasted to reach USD 9.8 trillion by 2029.
- Projections: Market is anticipated to reach between USD 90 billion and USD 555 billion by 2032-2034, driven by advancements in stem cell therapies, gene editing, and tissue engineering. The industry is experiencing a robust CAGR, with estimates generally falling between 16% and 31%.
- Market Drivers: North America is the leading market, accounting for over 58% of the global market share in 2024, supported by high healthcare spending and advanced biotech infrastructure. The U.S. market is projected to surpass USD 80 billion by 2033. Stem Cell and Gene Therapy: These subsegments are witnessing the fastest growth due to increased investment and regulatory approvals for treating genetic and degenerative disorders.
Steve Rubakh, CEO of MedWell Ai, comments:
“I am pleased to announce this consolidation to create a world-class state-of-the-art regenerative wellness company. By owning and aligning distribution, laboratories, biologics, and retail care models, MedWell Ai will create a complete wellness eco-system, designed to reduce supply chain inefficiencies, strengthen quality control, improve reliability, and enable disciplined national expansion through a scalable operating strategy. With the proposed consolidation, the Company intends to announce shortly, bringing a seasoned and talented management team to operate all three verticals. In addition, the Company is entertaining other additional strategic acquisitions it will be targeting in the coming months, as part of our quest to make MedWell Ai the #1 Regenerative Wellness & Medical Platform in the World".
Safe Harbor Statement:
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.
InvestorWire Service Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ**
How does MedWell Ai's strategy of consolidation and acquisition, particularly with companies like Ageless Cosmetic Surgery Centers and Apollo BioWellness, position it in the competitive landscape of the health and wellness market, especially for "Mountain West Airls Inc Unified MWAI"?
What specific measures does MedWell Ai plan to implement to ensure the successful integration of the acquired entities and maintain a disciplined operating strategy in line with the ambitious growth projections for "Mountain West Airls Inc Unified MWAI"?
Given the rapid growth anticipated by the regenerative medicine market, how will MedWell Ai capitalize on trends in stem cell therapies and gene editing to enhance its product offering, and how does "Mountain West Airls Inc Unified MWAI" fit into this vision?
Considering the projected revenue growth from $14 million in 2025 to over $25 million in 2026, what are the key risks that MedWell Ai anticipates that could impact these projections, particularly those related to "Mountain West Airls Inc Unified MWAI"?
**MWN-AI FAQ is based on asking OpenAI questions about Resonate Blends Inc (OTC: KOAN).
NASDAQ: KOAN
KOAN Trading
0.0% G/L:
$0.0016 Last:
510,069 Volume:
$0.0016 Open:
